• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症门诊患者中使用长效和口服抗精神病药物停药情况:一项为期 12 个月的观察性研究中匹配队列的比较。

Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.

机构信息

Intercontinental Information Sciences, Eli Lilly Australia Pty Ltd, Macquarie Park, NSW, Australia.

出版信息

Int J Clin Pract. 2011 Sep;65(9):945-53. doi: 10.1111/j.1742-1241.2011.02743.x.

DOI:10.1111/j.1742-1241.2011.02743.x
PMID:21849009
Abstract

AIMS

This study compared all-cause medication discontinuation (any switch, augmentation or medication discontinuation) in matched cohorts of patients with schizophrenia who were initiated on depot or oral antipsychotics. Other objectives included between-group comparisons of resource use, and clinical and functional outcomes.

METHODS

This post hoc analysis of a one-year, multicentre, prospective, observational study included outpatients with schizophrenia who required a change in their antipsychotic medication because of a physician-perceived risk of medication non-adherence. Patients were matched 1 : 1 using an optimal algorithm with rank-based Mahalanobis distances. All-cause medication discontinuation was compared using the Klein and Moeschberger test for survival and hazard ratios (HR) with 95% confidence intervals (CI) were calculated using a Cox proportional hazards model, stratifying on matched pairs.

RESULTS

Forty patients who initiated a depot antipsychotic could be matched to patients who initiated an oral antipsychotic. Fewer depot-treated patients discontinued their antipsychotic medication at least once compared with oral-treated patients [20% (8/40) vs. 40% (16/40)]. Depot-treated patients discontinued their medication later (Klein and Moeschberger test p = 0.025) and were less likely to discontinue their initial antipsychotic medication [HR = 0.33 (95% CI, 0.12-0.92), p = 0.033] than oral-treated patients. There were few differences in resource use and no differences in clinical and functional outcomes between cohorts.

CONCLUSION

In this matched-cohort analysis, patients with schizophrenia who were considered to be non-adherent with their prior oral antipsychotics were less likely to discontinue their medication for any cause if they were initiated on depot compared with oral antipsychotics.

摘要

目的

本研究比较了因医生认为药物依从性风险而需要更换抗精神病药物的精神分裂症患者,接受长效和口服抗精神病药物治疗的全因药物停药(任何换药、加药或停药)情况。其他目标包括组间资源利用、临床和功能结局比较。

方法

这是一项为期 1 年、多中心、前瞻性、观察性研究的事后分析,纳入了因医生认为药物依从性风险而需要更换抗精神病药物的精神分裂症门诊患者。根据最优算法和基于等级的马哈拉诺比斯距离对患者进行 1:1 匹配。使用生存 Klein 和 Moeschberger 检验和 Cox 比例风险模型比较全因药物停药,该模型对匹配对进行分层,并计算危险比(HR)及其 95%置信区间(CI)。

结果

40 例起始长效抗精神病药物的患者可以与起始口服抗精神病药物的患者匹配。与口服治疗组相比,长效治疗组至少停药一次的患者更少[20%(8/40)比 40%(16/40)]。长效治疗组停药时间较晚(Klein 和 Moeschberger 检验,p = 0.025),初始抗精神病药物停药的可能性较小[HR = 0.33(95% CI,0.12-0.92),p = 0.033]。两组资源利用差异较小,临床和功能结局无差异。

结论

在这项匹配队列分析中,与起始口服抗精神病药物相比,被认为对先前口服抗精神病药物依从性差的精神分裂症患者,如果起始长效抗精神病药物治疗,因任何原因停药的可能性更小。

相似文献

1
Medication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational study.精神分裂症门诊患者中使用长效和口服抗精神病药物停药情况:一项为期 12 个月的观察性研究中匹配队列的比较。
Int J Clin Pract. 2011 Sep;65(9):945-53. doi: 10.1111/j.1742-1241.2011.02743.x.
2
Comparison of treatment discontinuation and hospitalization among nonadherent patients initiating depot or oral typical antipsychotic medications.比较起始使用长效或口服典型抗精神病药物的不依从患者的停药和住院情况。
Int Clin Psychopharmacol. 2012 Sep;27(5):275-82. doi: 10.1097/YIC.0b013e328354db12.
3
Changes in adherence and treatment costs following initiation of oral or depot typical antipsychotics among previously non-adherent patients with schizophrenia.先前未坚持服药的精神分裂症患者开始使用口服或长效典型抗精神病药物后依从性和治疗成本的变化。
Hum Psychopharmacol. 2013 Sep;28(5):438-46. doi: 10.1002/hup.2328. Epub 2013 Jun 15.
4
A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.长效注射用利培酮与口服非典型抗精神病药物持续治疗首发精神分裂症患者的随机对照试验:初始依从性结果
J Clin Psychiatry. 2009 Oct;70(10):1397-406. doi: 10.4088/JCP.09m05284yel.
5
Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: a nationwide study in Hungary.比较第二代抗精神病药物长效针剂和口服制剂治疗精神分裂症的疗效:匈牙利全国性研究。
Eur Neuropsychopharmacol. 2013 Nov;23(11):1383-90. doi: 10.1016/j.euroneuro.2013.02.003. Epub 2013 Mar 7.
6
Predictors for starting depot administration of risperidone in chronic users of antipsychotics.抗精神病药物长期使用者开始使用利培酮长效注射剂的预测因素。
J Clin Psychopharmacol. 2008 Dec;28(6):625-30. doi: 10.1097/JCP.0b013e31818a6d10.
7
Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.精神分裂症患者早期不依从口服抗精神病药物对临床和经济结局的影响。
Adv Ther. 2013 Mar;30(3):286-97. doi: 10.1007/s12325-013-0016-5. Epub 2013 Mar 8.
8
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.早期精神病的口服与注射用抗精神病药物治疗:两项研究的事后比较
Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.
9
Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.长效与口服抗精神病药治疗精神分裂症的疗效和效果:综合不同研究设计的结果。
J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19.
10
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.抗精神病药物在精神分裂症门诊护理中的三年疗效:观察性研究与随机对照研究结果
Eur Neuropsychopharmacol. 2007 Mar;17(4):235-44. doi: 10.1016/j.euroneuro.2006.09.005. Epub 2006 Nov 29.

引用本文的文献

1
Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia.在精神分裂症患者的实际治疗中与帕利哌酮长效注射剂维持治疗相关因素的调查。
Ther Adv Psychopharmacol. 2025 Apr 22;15:20451253251333987. doi: 10.1177/20451253251333987. eCollection 2025.
2
Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.长效注射型抗逆转录病毒疗法在实践中的应用:一项混合方法实施研究,评估在高风险人群和替代低门槛护理场所使用长效注射型抗逆转录病毒疗法的可行性。
AIDS Patient Care STDS. 2024 May;38(5):221-229. doi: 10.1089/apc.2024.0048. Epub 2024 Apr 24.
3
Oral versus long-acting injectable antipsychotic in first episode schizophrenia: A 12 weeks interventional study.首发精神分裂症患者口服与长效注射用抗精神病药物的比较:一项为期12周的干预性研究。
Indian J Psychiatry. 2023 Apr;65(4):404-411. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_389_22. Epub 2023 Apr 11.
4
High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.精神障碍患者长效注射用抗精神病药物治疗期间的高停药率
Biomedicines. 2023 Jan 22;11(2):314. doi: 10.3390/biomedicines11020314.
5
Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta-analysis of observational studies.精神分裂症复发定义对口服与注射用抗精神病药比较疗效的影响:观察性研究的系统评价和荟萃分析。
Pharmacol Res Perspect. 2022 Feb;10(1):e00915. doi: 10.1002/prp2.915.
6
Schizophrenia population health management: perspectives of and lessons learned from population health decision makers.精神分裂症人群健康管理:人群健康决策制定者的观点和经验教训。
J Manag Care Spec Pharm. 2021 Oct;27(10-a Suppl):S2-S13. doi: 10.18553/jmcp.2021.27.10-aa.s2.
7
The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?长效抗逆转录病毒疗法提高依从性的前景:有哪些数据?
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:23259582211009011. doi: 10.1177/23259582211009011.
8
The Impact of Antipsychotic Formulations on Time to Medication Discontinuation in Patients with Schizophrenia: A Dutch Registry-Based Retrospective Cohort Study.抗精神病药物剂型对精神分裂症患者停药时间的影响:一项荷兰登记处基于回顾性队列研究。
CNS Drugs. 2021 Apr;35(4):451-460. doi: 10.1007/s40263-021-00802-3. Epub 2021 Apr 10.
9
Attitudes of European physicians towards the use of long-acting injectable antipsychotics.欧洲医生对长效注射用抗精神病药物使用的态度。
BMC Psychiatry. 2020 Mar 14;20(1):123. doi: 10.1186/s12888-020-02530-2.
10
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres.长效注射抗精神病药:博洛尼亚社区精神卫生中心新门诊治疗的 6 个月随访。
PLoS One. 2019 Feb 15;14(2):e0211938. doi: 10.1371/journal.pone.0211938. eCollection 2019.